Importance of depressive symptoms in schizophrenia and theirs pharmacotherapies;Şizofrenide depresif belirtilerin önemi ve psikofarmakolojik saǧaltimi

Klinik Psikofarmakoloji Bulteni

Volumn 16, Issue 1, 2006, Pages 52-62

  Kayahan, Bülent ^a   Veznedaroǧlu, Baybars ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antidepressants; Atypical antipsychotics; Depression; Pharmacotherapy; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; HUMAN; MORBIDITY; MORTALITY; PROGNOSIS; RECURRENT DISEASE; REVIEW; SCHIZOPHRENIA; SUICIDE; SYMPTOMATOLOGY; TURKEY (REPUBLIC);

EID: 33645553319     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. McGlashan TH, Fenton WS. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophrenia Bull 1992;18:228
2. Davidson L. Schizophrenia: diagnosis and phenomenology. Current Op Psychiatry 1995;8:21-24
3. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Sch Bull 1991;17:75-98
4. Van der Does AVJ. A dimensional and categorical approach to the symptomatology of recent onset schizophrenia. J Nerv Ment Dis 1993;181:744-749
5. Mc Glashan TH. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976;33:231-239
6. Liddle PF. Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 1993;88:243-247
7. Knights A. Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981;38:801-806
8. Johnson DAW. The side effects of fluphenazine decanoate. Br J Psychiatry 1973;123:519-522
9. Peuskens J. Proper psychosocial rehabilitation for stabilised patients with schizophrenia:the role of new therapies. Eur Neuropsychopharmacol 1996; Suppl 2:S7-S12
10. Koreen AR. Depression in first episode schizophrenia. Am J Psychiatry 1993;150:1643-1648
11. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life ? J Clin Psychiatry 1999;60 (Suppl 5):S23-S29
12. Bechdolf A, Klosterkotter J, Hambrecht M, Knost B, Kuntermann C, Schiller S, Pukrop S. Eur Arch Psychiatry Clin Neurosci 2003;253:228-235
13. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 2003;108:297-303
14. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA. Subjective quality of life in first epizode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res 2004;129:141-147
15. Tollefson GD. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258
16. Hogarty GE, McEvoy JP, Ulrich RF. Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995;52:29
17. Prusoff BA, Williams DH, Weissmann MM. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amityriptiline added to perphenazine. Arch Gen Psychiatry 1979;36:569-575
18. Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB. Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. Arch Gen Psychiatry 1987; 44:533-539
19. Siris SG, Sellew AP, Frechen K. Antidepressants in the treatment of post-psychotic depression in schizophrenia: drug interactions and other considerations. Clin Chem 1988;34:837-840
20. Siris SG, Mason SE, Bermanzohn PC. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacol Bull 1990;26:91-94
21. Siris SG, Bermanzohn PC, Mason SE. Adjunctive imipramine for dysphoric schizophrenic patients with past histories of cannabis abuse. Prog Neuropschopharmacol Biol Psychiatry 1992;16:539-547
22. Siris SG, Bermanzohn PC, Mason SE. Maintanence imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994;51:109-115
23. Siris SG, Pollack S, Bermanzohn PC. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia. Schizophr Res 2000;44:187-192
24. Plasky. Antidepresant usage in schizophrenia. Schizophr Bull 1991;17:649-657
25. Goff DC, Brotman AW, Waites M. Trial of fluoksetin added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990;147:492-494
26. Caroli F, Baldocci-Epinette C, Ribeyre P. Antidepressant treatment of schizophrenic patients. Encephale 1993;19:393-396
27. Spina E, Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, DiRosa AE, Caputi AP. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994;9:281-285
28. Taiminen TJ, Syvalahti E, Saarijarvi S, Niemi H, Lehto H, Ahola V, Salokangas RK. Citalopram as an adjuant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int Clin Psychopharmacol 1997;12:31-35
29. Kasckow JW, Mohamed S, Thallosinos A. Citalopram augmentation of antipsychotic treatment in older schizophrenic patients. Int J Geriatr Psychiatry 2001;16:1163-1167
30. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L. Double-blind, placebo-controlled comparison of the efficacy of sertraline as the treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002;22:20-25
31. Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol 2003;17:107-112
32. Kirli S, Calişkan M. A comperative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 1998;33:103-111
33. Mazeh D, Melamed Y, Elizur A. Venlafaxine in the treatment of resistant postpsychotic depressive symptoms of schizophrenia. J Clin Psychopharmacol 1999;19:284-285
34. Mazeh D, Shabal B, Saraf R, Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacology 2004;24:633-655
35. Nakanishi S, Kunugi H, Takahashi T. Efficacy of milnacipran for depressive symptoms in schizophrenia spectrum disorders. Psychiatry Clin Neurosci. 2004;58:226-227
36. van Kammen DP, Alexander PE, Bunney WE Jr. Lithium treatment in post-psychotic depression. Br J Psychiatry 1980;136:479-485
37. Lerner Y, Mintzer Y, Schestatzky M. Lithium combined with haloperidol in schizophrenic patients. Br J Psychiatry 1988;153:359-362
38. Terao T, Oga T, Nozaki S, Ohta A, Ohtsubo Y, Yamamato S, Zamami M, Okada M. Lithium addition to neuroleptic treatment in chronic schizophrenia: a randomized, double blind, placebo-controlled, cross- over study. Acta Psychiatr Scand 1995;92:220-224
39. Boyer P, Lecrubier Y, Rein W. Methodological constraints in evaluating anti-deficit effects. Encephale 1996;22:25-27
40. Llorca PM, Lancon C, Reine G. Psychoses, mood, suicidal tendencies and clozapine. Encephale 1997;23:431-436
41. Abraham G, Nair C, Tracy JI, Simpson GM, Josiassen RC. The effects of clozapine on symptom clusters in treatment-refractory patients. J Clin Psychopharmacol 1997;17:49-53
42. Altamura AC, Bignotti S, Tura G, Curreli R, Pioli R. Depressive symptomatology during clozapine treatment: two case reports. Eur Neuropsychopharmacol 1998;8:239-240
43. Fleischhakker C. Depressive symptoms and biogenic amines as predictors of treatment response in schizophrenic illnesses in childhood and adolescence. Z Kinder Jugendpsychiatr Psychother 1998 Dec;26:235-243
44. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
45. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSept Study. J Clin Psychiatry 1999;60 (suppl12):47-50
46. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeosis M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S; International Suicide Prevention Trial Study Group. Arch Gen Psychiatry 2003;60:82-91
47. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of chizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546
48. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294-298
49. Asleigh EA. A syndrome of increased affect in response to risperidone among patients with schiozphrenia. Psychiatr Serv 1998;49:526-528
50. Peuskens J, Van Baelen B, Smedt C, Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000;15:343-349
51. Tollefson GD, Sanger TM, Beasley CM, Tran PV . A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-810
52. Tollefson GD. The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999;46:365-373
53. Lindenmayer JP, Czabor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M. J Clin Psychiatry 2004;65:551-556
54. Khouzam HR. Treatment of depressive mood in schizophrenia with the atypical antipsycotic quetiapine. Depress Anxiety 2000;11:80-82
55. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 2003;17:210-215
56. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Neuropsychopharmacology 1999;20:491-505
57. Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res 1999;35 (Suppl):S13-S21